Autopsy report · NCT01865084
A Study of Tadalafil for Duchenne Muscular Dystrophy
Cause of deathFutility
“The study is being terminated for lack of efficacy”
Life of this trial
- Registered 4 months before it started.
- Ran for about 2 years 6 months before it stopped.
- 331 participants enrolled.
- Results were posted on the registry 1 year after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Conditions
- Muscular Dystrophy, Duchenne
- Interventions
- Tadalafil; Placebo
- Participants
- 331
- Sites
- 62
- Countries
- Argentina, Belgium, Canada, France, Germany, Italy, Japan, Netherlands, Puerto Rico, Russia, South Korea, Spain and more
Trials that died the same way
- Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM
“The study was terminated due to lack of efficacy.” - Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole
“This study was terminated for reasons not related to efficacy or safety” - Dasatinib in Polycythemia Vera
“This study was terminated due to lack of efficacy.” - A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)
“This study was terminated due to limited efficacy and not due to safety reasons” - A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration
“This study was terminated due to a lack of efficacy.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.